DHR
NEUTRAL
$195.5
Live
Danaher Corporation · NYSE
Target $256.05
(+31.0%)
$180.03
52W Range
$242.8
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 21, 2026
Market cap
$138.36B
P/E
38.94
ROE
7.1%
Profit margin
14.7%
Debt/Equity
0.37
Dividend yield
0.82%
AI Analysis
AI-powered fundamental assessment
Confidence
85%
Danaher Corporation presents a dichotomy between strong operational quality and poor valuation metrics. The deterministic baseline is weak, with a Piotroski F-Score of 4/9 (Stable) and a current price of $195.50 that significantly exceeds both the Graham Number ($91.62) and the Intrinsic Value ($129.26). While the balance sheet is exceptionally healthy with low debt/equity (0.37), the stock is trading at a steep premium. Despite a 'Strong Buy' analyst consensus and a high target price of $256.05, the bearish technical trend and insider selling suggest caution.
Key Strengths
Very low Debt/Equity ratio (0.37) indicating high financial solvency
Strong Gross Margins (59.23%) reflecting significant pricing power
Consistent long-term track record of earnings beats over 25 quarters
Sustainable dividend payout ratio (25.45%)
Strong analyst support with a 'Strong Buy' consensus
Key Risks
Significant overvaluation relative to Graham and Intrinsic value models
Bearish technical trend (0/100) and negative 6-month price performance
Slow organic revenue growth (4.60% YoY)
Recent Q/Q EPS contraction of -11.1%
Bearish insider sentiment with net selling activity
AI Fair Value Estimate
Based on comprehensive analysis
$152.4
-22.0% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
53
Moderate
30
55
80
60
40
AI Verdict
Stable but Overvalued
Key drivers: Low debt, High valuation premium, Slow revenue growth, Strong historical earnings consistency
Confidence
90%
Value
30/100
Ref P/E, PEG, Graham Number
Positives
- Forward P/E (21.49) is lower than trailing P/E
Watchpoints
- Price is >100% above Graham Number
- Price is ~51% above Intrinsic Value
- High P/E of 38.94
Future
55/100
Ref Growth rates
Positives
- Earnings growth (12.5%) outpaces revenue growth
- Strong analyst target price ($256.05)
Watchpoints
- Low YoY revenue growth (4.6%)
- Recent Q/Q EPS decline
Past
80/100
Ref Historical trends
Positives
- Exceptional 25-quarter earnings beat history
- Consistent profitability margins
Watchpoints
- Negative 3Y and 5Y price change
Health
60/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Low Debt/Equity (0.37)
- Healthy Current Ratio (1.87)
Watchpoints
- Piotroski F-Score of 4/9 is only 'Stable', not 'Strong'
Dividend
40/100
Ref Yield, Payout
Positives
- Very low payout ratio (25.45%)
Watchpoints
- Very low dividend yield (0.82%)
- Low overall dividend strength score (25/100)
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$195.5
Analyst Target
$256.05
Upside/Downside
+31.0%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for DHR and closest competitors.
Updated 2026-04-20
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
DHR
Danaher Corporation
Primary
|
-7.7% | -11.3% | +6.4% | -5.9% | +3.5% | -0.2% |
|
SYK
Stryker Corporation
Peer
|
+42.9% | +18.0% | -10.8% | -9.0% | -14.6% | +0.9% |
|
PFE
Pfizer Inc.
Peer
|
+1.1% | -17.2% | +24.9% | +8.7% | +4.8% | +4.8% |
|
VRTX
Vertex Pharmaceuticals Incorporated
Peer
|
+109.6% | +41.7% | -7.9% | +14.0% | -8.1% | -0.5% |
|
GILD
Gilead Sciences, Inc.
Peer
|
+144.5% | +69.7% | +29.3% | +10.8% | -3.2% | -4.9% |
DHR
Danaher Corporation
Primary
5Y
-7.7%
3Y
-11.3%
1Y
+6.4%
6M
-5.9%
1M
+3.5%
1W
-0.2%
SYK
Stryker Corporation
Peer
5Y
+42.9%
3Y
+18.0%
1Y
-10.8%
6M
-9.0%
1M
-14.6%
1W
+0.9%
PFE
Pfizer Inc.
Peer
5Y
+1.1%
3Y
-17.2%
1Y
+24.9%
6M
+8.7%
1M
+4.8%
1W
+4.8%
VRT
Vertex Pharmaceuticals Incorporated
Peer
5Y
+109.6%
3Y
+41.7%
1Y
-7.9%
6M
+14.0%
1M
-8.1%
1W
-0.5%
GIL
Gilead Sciences, Inc.
Peer
5Y
+144.5%
3Y
+69.7%
1Y
+29.3%
6M
+10.8%
1M
-3.2%
1W
-4.9%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
38.94
Forward P/E
21.49
PEG Ratio
1.26
P/B Ratio
2.63
P/S Ratio
5.63
EV/Revenue
6.24
EV/EBITDA
19.57
Market Cap
$138.36B
Profitability
Profit margins and return metrics
Profit Margin
14.71%
Operating Margin
22.17%
Gross Margin
59.23%
ROE
7.05%
ROA
4.18%
Growth
Revenue and earnings growth rates
Revenue Growth
+4.6%
Earnings Growth
+12.5%
Q/Q Revenue Growth
+4.59%
Q/Q Earnings Growth
+10.2%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.37
Low debt
Current Ratio
1.87
Good
Quick Ratio
1.4
Good
Cash/Share
$6.53
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$6.8B
Gross Margin
58.0%
Op. Margin
22.0%
Net Margin
17.5%
Total Assets
$83.5B
Liabilities
$30.9B
Equity
$52.5B
Debt/Equity
0.59x
Operating CF
$2.1B
CapEx
$-0.4B
Free Cash Flow
$1.7B
FCF Yield
82%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-04-21
$N/A
2026-01-28
$1.68
-0.6% surprise
2025-10-21
$1.89
+9.8% surprise
2025-07-22
$1.8
+9.5% surprise
Healthcare Sector Comparison
Comparing DHR against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
P/E Ratio
38.94
This Stock
vs
75.44
Sector Avg
-48.4%
(Discount)
Return on Equity (ROE)
7.05%
This Stock
vs
-88.14%
Sector Avg
-108.0%
(Below Avg)
Profit Margin
14.71%
This Stock
vs
-16.28%
Sector Avg
-190.4%
(Weaker)
Debt to Equity
0.37
This Stock
vs
2.66
Sector Avg
-85.9%
(Less Debt)
Revenue Growth
4.6%
This Stock
vs
124.04%
Sector Avg
-96.3%
(Slower)
Current Ratio
1.87
This Stock
vs
4.47
Sector Avg
-58.1%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
DHR
Danaher Corporation
|
NEUTRAL | $138.36B | 38.94 | 7.1% | 14.7% | $195.5 | |
|
SYK
Stryker Corporation
|
NEUTRAL | $126.27B | 39.2 | 15.1% | 12.9% | $329.69 | Compare |
|
PFE
Pfizer Inc.
|
BEARISH | $162.54B | 21.01 | 8.9% | 12.4% | $28.57 | Compare |
|
VRTX
Vertex Pharmaceuticals Incorporated
|
NEUTRAL | $113.44B | 28.9 | 22.5% | 32.9% | $446.54 | Compare |
|
GILD
Gilead Sciences, Inc.
|
NEUTRAL | $164.96B | 19.6 | 40.7% | 28.9% | $132.9 | Compare |
DHR
Danaher Corporation
NEUTRAL
Mkt Cap
$138.4B
P/E
38.9
ROE
7.1%
Price
$195.5
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-27 | BLAIR RAINER M | Chief Executive Officer | Stock Award | 17,566 | - |
| 2026-02-27 | GUTIERREZ-RAMOS JOSE-CARLOS | Officer | Stock Award | 6,647 | - |
| 2026-02-27 | MCGREW MATTHEW | Officer | Stock Award | 5,935 | - |
| 2026-02-27 | BOUDA CHRISTOPHER | Officer | Stock Award | 1,247 | - |
| 2026-02-27 | COUCHARA GEORGEANN F. | Officer | Stock Award | 4,748 | - |
| 2026-02-27 | RILEY CHRISTOPHER PAUL | Officer | Stock Award | 6,172 | - |
| 2026-02-27 | SAWYER MONTGOMERY JULIE A | Officer | Stock Award | 6,172 | - |
| 2026-02-27 | MILOSEVICH GREGORY M | Officer | Stock Award | 4,273 | - |
| 2026-02-27 | GUGINO MATTHEW E. | Chief Financial Officer | Stock Award | 3,988 | - |
| 2026-02-27 | RALES MITCHELL P | Officer and Director | Gift | 71,648 | - |
| 2026-02-27 | GRAY ROBERT BRADLEY | Officer | Stock Award | 2,849 | - |
| 2026-02-27 | LEIKEN JONATHAN B | Officer | Stock Award | 2,374 | - |
| 2026-02-19 | MILOSEVICH GREGORY M | Officer | Sale | 1,320 | $274,575 |
| 2026-02-19 | MILOSEVICH GREGORY M | Officer | Option Exercise | 1,320 | $77,339 |
| 2026-02-04 | BLAIR RAINER M | Chief Executive Officer | Stock Award | 8,474 | - |
BLAIR RAINER M
Chief Executive Officer
2026-02-27
17,566 shares
GUTIERREZ-RAMOS JOSE-CARLOS
Officer
2026-02-27
6,647 shares
MCGREW MATTHEW
Officer
2026-02-27
5,935 shares
BOUDA CHRISTOPHER
Officer
2026-02-27
1,247 shares
COUCHARA GEORGEANN F.
Officer
2026-02-27
4,748 shares
RILEY CHRISTOPHER PAUL
Officer
2026-02-27
6,172 shares
SAWYER MONTGOMERY JULIE A
Officer
2026-02-27
6,172 shares
MILOSEVICH GREGORY M
Officer
2026-02-27
4,273 shares
GUGINO MATTHEW E.
Chief Financial Officer
2026-02-27
3,988 shares
RALES MITCHELL P
Officer and Director
2026-02-27
71,648 shares
GRAY ROBERT BRADLEY
Officer
2026-02-27
2,849 shares
LEIKEN JONATHAN B
Officer
2026-02-27
2,374 shares
MILOSEVICH GREGORY M
Officer
2026-02-19
1,320 shares
·
$274,575
MILOSEVICH GREGORY M
Officer
2026-02-19
1,320 shares
·
$77,339
BLAIR RAINER M
Chief Executive Officer
2026-02-04
8,474 shares
Insider transactions can signal confidence or concerns about company prospects
SEC Filings
Recent regulatory filings from the SEC EDGAR database
8-K
DEF 14A
Data sourced from SEC EDGAR. AI summaries generated automatically.
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
22 analysts
Baird
2026-04-17
Outperform
Outperform
Barclays
2026-04-14
Overweight
Overweight
Goldman Sachs
2026-04-13
Buy
Buy
Evercore ISI Group
2026-04-06
Outperform
Outperform
JP Morgan
2026-01-29
Overweight
Overweight
Jefferies
2026-01-29
Buy
Buy
TD Cowen
2026-01-07
Buy
Buy
Guggenheim
2026-01-05
Buy
Buy
Wells Fargo
2025-12-15
Equal-Weight
Equal-Weight
Goldman Sachs
2025-12-09
Buy
Past News Coverage
Recent headlines mentioning DHR from our newsroom.
Newest → oldest
No matching news yet.